28042952|t|Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer
28042952|a|Hypoxic microenvironment is critically involved in the response of non-small cell lung cancer (NSCLC) to chemotherapy, the mechanisms of which remain largely unknown. Here, we found that NSCLC patients exhibited increased chemotherapeutic resistance when complicated by chronic obstructive pulmonary disease (COPD), a critical cause of chronic hypoxemia. The downregulation of uncoupling protein 2 (UCP2), which is attributed to hypoxia-inducible factor 1 (HIF-1)-mediated suppression of the transcriptional factor peroxisome proliferator-activated receptor γ (PPARγ), was involved in NSCLC chemoresistance, and predicted a poor survival rate of patients receiving routine chemotherapy. UCP2 suppression induced reactive oxygen species production and upregulation of the ABC transporter protein ABCG2, which leads to chemoresistance by promoting drug efflux. UCP2 downregulation also altered metabolic rates as shown by elevated glucose uptake and reduced oxygen consumption. These data suggest that UCP2 is a key mediator of hypoxia -triggered chemoresistance of NSCLCs, which can be potentially targeted in clinical treatment of chemo-refractory NSCLCs.
28042952	0	20	Uncoupling protein 2	T103	UMLS:C0536847
28042952	21	35	downregulation	T038	UMLS:C0013081
28042952	39	46	hypoxia	T038	UMLS:C0242184
28042952	55	65	repression	T038	UMLS:C0920533
28042952	69	113	peroxisome proliferator-activated receptor γ	T103	UMLS:C0166417
28042952	123	138	chemoresistance	T038	UMLS:C1514892
28042952	142	168	non-small cell lung cancer	T038	UMLS:C0007131
28042952	169	176	Hypoxic	T038	UMLS:C0242184
28042952	177	193	microenvironment	T082	UMLS:C0014406
28042952	236	262	non-small cell lung cancer	T038	UMLS:C0007131
28042952	264	269	NSCLC	T038	UMLS:C0007131
28042952	274	286	chemotherapy	T058	UMLS:C3665472
28042952	356	361	NSCLC	T038	UMLS:C0007131
28042952	391	418	chemotherapeutic resistance	T038	UMLS:C1514892
28042952	439	476	chronic obstructive pulmonary disease	T038	UMLS:C0024117
28042952	478	482	COPD	T038	UMLS:C0024117
28042952	505	522	chronic hypoxemia	T033	UMLS:C0745188
28042952	528	542	downregulation	T038	UMLS:C0013081
28042952	546	566	uncoupling protein 2	T103	UMLS:C0536847
28042952	568	572	UCP2	T103	UMLS:C0536847
28042952	598	624	hypoxia-inducible factor 1	T103	UMLS:C0215848
28042952	626	631	HIF-1	T103	UMLS:C0215848
28042952	642	653	suppression	T038	UMLS:C0038855
28042952	661	683	transcriptional factor	T103	UMLS:C0040648
28042952	684	728	peroxisome proliferator-activated receptor γ	T103	UMLS:C0166417
28042952	730	735	PPARγ	T103	UMLS:C0166417
28042952	754	759	NSCLC	T038	UMLS:C0007131
28042952	760	775	chemoresistance	T038	UMLS:C1514892
28042952	842	854	chemotherapy	T058	UMLS:C3665472
28042952	856	860	UCP2	T103	UMLS:C0536847
28042952	861	872	suppression	T038	UMLS:C1514892
28042952	881	904	reactive oxygen species	T103	UMLS:C0162772
28042952	920	932	upregulation	T038	UMLS:C0041904
28042952	940	963	ABC transporter protein	T103	UMLS:C0242738
28042952	964	969	ABCG2	T103	UMLS:C0761993
28042952	986	1001	chemoresistance	T038	UMLS:C1514892
28042952	1015	1026	drug efflux	T038	UMLS:C1512072
28042952	1028	1032	UCP2	T103	UMLS:C0536847
28042952	1033	1047	downregulation	T038	UMLS:C0013081
28042952	1098	1112	glucose uptake	T038	UMLS:C1159527
28042952	1125	1143	oxygen consumption	T201	UMLS:C0030055
28042952	1169	1173	UCP2	T103	UMLS:C0536847
28042952	1195	1202	hypoxia	T038	UMLS:C0242184
28042952	1214	1229	chemoresistance	T038	UMLS:C1514892
28042952	1233	1239	NSCLCs	T038	UMLS:C0007131
28042952	1278	1296	clinical treatment	T058	UMLS:C1516635
28042952	1317	1323	NSCLCs	T038	UMLS:C0007131